Abstract
The available treatments for oral candidosis have proved to be more efficacious with the use of new and known antifungal drugs. The success of these is directly related to the correct diagnosis, identification, and correction of etiological factors and the commitment of the patient. In the absence of some of these factors, the antifungal therapy results only in a brief relief from disease, triggering relapses. This chapter presents the main drugs used in the treatment of oral and oropharyngeal candidosis, their functioning in the human body, and their mechanism of action in the destruction of the pathogenic agent.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmed TA, El-Say KM et al (2012) Miconazole nitrate oral disintegrating tablets: in vivo performance and stability study. Clin Infect Dis 54(10):1480–1484
Akpan A, Morgan R (2002) Oral candidiasis. Postgrad Med J 78(922):455–459
Andes D, Marchillo K et al (2004) Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 48(1):137–142
Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46(2):451–457
Bensadoun RJ, Daoud J et al (2008) Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 112(1):204–211
Bozzette SA (2005) Fluconazole prophylaxis in HIV disease, revisited. Clin Infect Dis 41(10):1481–1482
Collins CD, Cookinham S et al (2011) Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability. Patient Prefer Adherence 5:369–374
Cupp-Vickery JR, Garcia C, Hofacre A, McGee-Estrada K (2001) Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. J Mol Biol 311(1):101–110
Giannini PJ, Shetty KV (2011) Diagnosis and management of oral candidiasis. Otolaryngol Clin North Am 44(1):231–240, vii
Greenspan D (1994) Treatment of oropharyngeal candidiasis in HIV-positive patients. J Am Acad Dermatol 31(3 Pt 2):S51–S55
Hamza OJ, Matee MI et al (2008) Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis 47(10):1270–1276
Hoang A (2001) Caspofungin acetate: an antifungal agent. Am J Health Syst Pharm 58(13):1206–1214
Ianas V, Matthias KR et al (2007) Role of posaconazole in the treatment of oropharyngeal candidiasis. Ther Clin Risk Manag 3(4):533–542
Kerridge D (1986) Mode of action of clinically important antifungal drugs. Adv Microb Physiol 27:1–72
Klotz SA (2006) Oropharyngeal candidiasis: a new treatment option. Clin Infect Dis 42(8):1187–1188
Lalla RV, Bensadoun RJ (2011) Miconazole mucoadhesive tablet for oropharyngeal candidiasis. Expert Rev Anti Infect Ther 9(1):13–17
Li D et al (2014) Efficacy and safety of probiotics in the treatment of Candida-associated stomatitis. Mycoses 57(3):141–146
Melkoumov A, Goupil M et al (2013) Nystatin nanosizing enhances in vitro and in vivo antifungal activity against Candida albicans. J Antimicrob Chemother 68(9):2099–2105
Millon L, Manteaux A et al (1994) Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 32(4):1115–1118
Morrison VA (2006) Echinocandin antifungals: review and update. Expert Rev Anti Infect Ther 4(2):325–342
Muzyka BC, Glick M (1995) A review of oral fungal infections and appropriate therapy. J Am Dent Assoc 126(1):63–72
Nagappan V, Deresinski S (2007) Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 45(12):1610–1617
Nairy HM, Charyulu NR et al (2011) A pseudo-randomised clinical trial of in situ gels of fluconazole for the treatment of oropharyngeal candidiasis. Trials 12:99
Neoh CF, Liew D et al (2011) Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. J Antimicrob Chemother 66(8):1906–1915
Neville BW, Damm DD, Allen CM, Bouquot JE (2002) Fungal and protozoal diseases. In: Neville BW, Damm DD, Allen CM, Bouquot JE (eds) Oral & maxillofacial pathology, 2nd edn. W.B. Saunders Company, Philadelphia, pp 189–211
Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD (2009) Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48(5):503–535
Park NH, Kang MOK (2011) Antifungal and antiviral agents. In: Mariotti A, Dowd FJ, Johnson B, Yagiela JA (eds) Pharmacology and therapeutics for dentistry, 6th edn. Mosby Inc. an affiliate of Elsevier Inc, Maryland Heights, pp 640–657
Patel PK, Erlandsen JE et al (2012) The changing epidemiology of oropharyngeal candidiasis in patients with HIV/AIDS in the era of antiretroviral therapy. AIDS Res Treat 2012:262471
Pemberton MN, Oliver RJ et al (2004) Miconazole oral gel and drug interactions. Br Dent J 196(9):529–531
Reboli AC, Rotstein C et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356(24):2472–2482
Rex JH, Rinaldi MG et al (1995) Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 39(1):1–8
Ruhnke M, Paiva JA et al (2012) Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect 18(7):680–687
Sangeorzan JA, Bradley SF et al (1994) Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 97(4):339–346
Sharon V, Fazel N (2010) Oral candidiasis and angular cheilitis. Dermatol Ther 23(3):230–242
Thompson GR 3rd, Patel PK et al (2010) Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109(4):488–495
Van Roey J, Haxaire M et al (2004) Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 35(2):144–150
Vazquez JA (2010) Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV AIDS (Auckl) 2:89–101
Vazquez JA, Sobel JD (2012) Miconazole mucoadhesive tablets: a novel delivery system. Clin Infect Dis 54(10):1480–1484
Vazquez JA, Skiest DJ et al (2006) A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 42(8):1179–1186
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Grégio, A.M.T., Veiga, F.F., Rinaldi, M., Bettega, P.V.C. (2015). Antifungals for Candidosis Treatment. In: Ribeiro Rosa, E. (eds) Oral Candidosis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47194-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-662-47194-4_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-47193-7
Online ISBN: 978-3-662-47194-4
eBook Packages: MedicineMedicine (R0)